GSK reports efficacy of Trexima against migraine

GlaxoSmithKline (GSK) has announced the results of a clinical study investigating the use of Trexima (sumatriptan/ naproxen sodium) in patients suffering from migraines.

The data from the trial involving over 1,100 patients revealed that those administered early with Trexima saw pain-relief at two and four hours, in addition to a pain-free response for two to 24 hours across multiple migraine attacks.

Results from the study were presented this week at the annual meeting of the American Academy of Neurology.

A single orally-administered tablet containing 500 mg of naproxen sodium and 85 mg of sumatriptan, the investigational pharmaceutical Trexima is currently being assessed by regulatory bodies as a therapy for migraines.

Richard Lipton, professor of neurology, epidemiology and social medicine at the Albert Einstein College of Medicine, commented that anticipation of migraine attacks can often prove stressful for patients.

“Patients want a treatment that works quickly and provides consistent relief for each attack,” he said.

He added that the results garnered from this trial were important, as they showed administration with the drug resulting in consistent pain-free results across multiple migraine attacks.

Earlier this week, GSK announced the positive results of two clinical studies of the extended release formulation of Lactimal (lamotrigine) as an add-on treatment for patients suffering from partial epilepsy.